60
Participants
Start Date
February 8, 2016
Primary Completion Date
January 30, 2018
Study Completion Date
July 30, 2019
Testosterone undecanoate and sunitinib or pazopanib
Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
A.I. Kryzhanovsky Krasnoyarsk Cancer Center, Krasnoyarsk
Kidney Cancer Research Bureau, Moscow
RUDN University, Moscow
City Clinical Oncology Center, Saint Petersburg
Kidney Cancer Research Bureau
OTHER